Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 421

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Clinical manifestations of the anti-IgLON5 disease

Open access
Gaig, Carles, Graus, Francesc, Compta, Yarko, Högl, Birgit, Bataller, Luis, Brüggemann, Norbert, Giordana, Caroline, Heidbreder, Anna, Kotschet, Katya, Lewerenz, Jan, Macher, Stefan, Martí, Maria J., Montojo, Teresa, Pérez-Pérez, Jesus, Puertas, Inmaculada, Seitz, Caspar, Simabukuro, Mateus, Téllez, Nieves, Wandinger, Klaus-Peter, Iranzo, Alex, Ercilla, Guadalupe, Sabater, Lidia, Santamaría, Joan, Dalmau, Josep · 2017 · Neurology

Abstract

OBJECTIVE: To report the presentation, main syndromes, human leukocyte antigen (HLA) association, and immunoglobulin G (IgG) subclass in the anti-IgLON5 disease: a disorder with parasomnias, sleep apnea, and IgLON5 antibodies. METHODS: This was a retrospective clinical analysis of 22 patients. The IgG subclass was determined using reported techniques. RESULTS: Patients' median age was 64 years (range 46-83). Symptoms that led to initial consultation included sleep problems (8 patients; 36%), gait abnormalities (8; 36%), bulbar dysfunction (3; 14%), chorea (2; 9%), and cognitive decline (1; 5%). By the time of diagnosis of the disorder, 4 syndromes were identified: (1) a sleep disorder with parasomnia and sleep breathing difficulty in 8 (36%) patients; (2) a bulbar syndrome including dysphagia, sialorrhea, stridor, or acute respiratory insufficiency in 6 (27%); (3) a syndrome resembling progressive supranuclear palsy (PSP-like) in 5 (23%); and (4) cognitive decline with or without chorea in 3 (14%). All patients eventually developed parasomnia, sleep apnea, insomnia, or excessive daytime sleepiness. HLA-DRB1*10:01 and HLA-DQB1*05:01 were positive in 13/15 (87%) patients; the DRB1*10:01 allele was 36 times more prevalent than in the general population. Among 16 patients with paired serum and CSF samples, 14 had IgLON5 antibodies in both, and 2 only in serum (both had a PSP-like syndrome). Twenty of 21 patients had IgG1 and IgG4 antibodies; the latter predominated in 16. CONCLUSIONS: Patients with IgLON5 antibodies develop a characteristic sleep disorder preceded or accompanied by bulbar symptoms, gait abnormalities, oculomotor problems, and, less frequently, cognitive decline. IgG4 subclass antibodies predominate over IgG1; we confirm a strong association with the HLA-DRB1*10:01 allele.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000003887

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 421

Metadata

Authors
Gaig, C., Graus, F., Compta, Y., Högl, B., Bataller, L., Brüggemann, N., Giordana, C., Heidbreder, A., Kotschet, K., Lewerenz, J., Macher, S., Martí, M. J., Montojo, T., Pérez-Pérez, J., Puertas, I., Seitz, C., Simabukuro, M., Téllez, N., Wandinger, K.-P., Iranzo, A., Ercilla, G., Sabater, L., Santamaría, J., & Dalmau, J.
Venue
Neurology
Published
2017-05-02
Volume
88
Issue
18
Pages
1736-1743
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2605154961
Cited by
421
References
18
FWCI
20.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical manifestations of the anti-IgLON5 disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000003887
The paper
Gaig, C., Graus, F., Compta, Y., Högl, B., Bataller, L., Brüggemann, N., Giordana, C., Heidbreder, A., Kotschet, K., Lewerenz, J., Macher, S., Martí, M. J., Montojo, T., Pérez-Pérez, J., Puertas, I., Seitz, C., Simabukuro, M., Téllez, N., Wandinger, K.-P., . . . Dalmau, J. (2017). Clinical manifestations of the anti-IgLON5 disease. Neurology. https://doi.org/10.1212/wnl.0000000000003887

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.